Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

A healthcare landscape going through seismic change

Pfizer’s quest to generate health innovation as an ageing demographic threatens society’s ability to treat people

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Shake-up at GSK could claim antibiotics unit and UK facilities

The firm says its plans, which are expected to lead to 320 job cuts, are not related to Brexit

- PMLiVE

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

- PMLiVE

GSK starts trial of Nucala to seek alternate indications

Asthma therapy drug to be used to target severe nasal polyposis

- PMLiVE

GSK makes case for revaccination with Shingrix

The pharma giant seeks regulatory approval to treat people aged 50 plus

Can Cinderella save us?

Basilea bags $72m upfront from Pfizer for antifungal license

Pfizer will also pay $427m in future milestone payments for Cresemba

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

dengue fever mosquito

GSK cues up regulatory filings for relapsing malaria drug

60% of patients on tafenoquine combination remained relapse-free for six months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links